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-To test the hypothesis that the vasodilator complement that produces arteriolar vasodilation during muscle contraction depends on both stimulus and contraction frequency, we stimulated four to five skeletal muscle fibers in the anesthetized hamster cremaster preparation in situ and measured the change in diameter of arterioles at a site of overlap with the stimulated muscle fibers. Diameter was measured before, during, and after 2 min of skeletal muscle contraction stimulated over a range of stimulus frequencies [4, 20, and 40 Hz; 15 contractions/min (cpm), 250 ms train duration] and a range of contraction frequencies (6, 15 , and 60 cpm; 20 Hz stimulus frequency, 250 ms train duration). Muscle fibers were stimulated in the absence and presence of an inhibitor of adenosine receptors [10 Ϫ6 M xanthine amine congener (XAC)], an ATP-dependent potassium (K ϩ ) channel inhibitor (10 Ϫ5 M glibenclamide), an inhibitor of a source of K ϩ by inhibition of voltage-dependent K ϩ channels [3 ϫ 10 Ϫ4 M 3,4-diaminopyridine (DAP)], and an inhibitor of nitric oxide synthase [10 Ϫ6 M N G -nitro-L-arginine methyl ester (L-NAME) ϩ 10 Ϫ7 S-nitroso-N-acetylpenicillamine (a nitric oxide donor)]. L-NAME inhibited the dilations at all stimulus frequencies and contraction frequencies except 60 cpm. XAC inhibited the dilations at all contraction frequencies and stimulus frequencies except 40 Hz. Glibenclamide inhibited all dilations at all stimulus and contraction frequencies, and DAP did not inhibit dilations at any stimulus frequencies while attenuating dilation at a contraction frequency of 60 cpm only. Our data show that the complement of dilators responsible for the vasodilations induced by skeletal muscle contraction differed depending on the stimulus and contraction frequency; therefore, both are important determinants of the dilators involved in the processes of arteriolar vasodilation associated with active hyperemia. stimulus frequency; contraction frequency; arteriole; skeletal muscle contraction; active hyperemia BLOOD FLOW TO ACTIVE SKELETAL muscle increases during contraction. It is hypothesized that active skeletal muscle cell metabolites are a source of vasodilators that cause active hyperemia during contraction, but there is little consensus as to the identity of the vasodilators involved. A host of potential metabolic vasodilators such as adenosine (ADO), hydrogen ions, decreased oxygen tension, carbon dioxide, phosphate, etc., as well as a host of endothelial-derived products and products of muscle activation such as nitric oxide (NO), potassium (K ϩ ), prostaglandins, ACh, ATP-dependent K ϩ (K ATP ) channels, etc. (for review, see Refs. 6, 18, 28, 36) , have been implicated in the processes of active hyperemia, but there is a general lack of agreement as to the relative importance of each. We have been investigating the impact of stimulation parameters in the processes of arteriolar vasodilation during active hyperemia to understand this general lack of agreement. We surmised that if the dilators are proposed to be products of skeletal muscle activation or metabolism then it stands to reason that if activation or metabolism is changed through different stimulation parameters then the dilators being produced may also change. Thus, to understand the impact that stimulation parameters have on the production of different vasodilators in active hyperemia, we have investigated the effects of stimulation parameters as a determinant of the dilators produced in response to skeletal muscle contraction.
We have previously shown that stimulus frequency is an important determinant of the dilators produced in response to a single contraction. A single stimulus producing a twitch contraction produced a rapid vasodilation, and increasing stimulus frequency resulted in a biphasic dilation implying the presence of two vasodilators (40) . Further increases in stimulus frequency resulted in a single, larger, prolonged dilation, whether this dilation is the result of the production of more of the dilators produced at lower stimulus frequencies or whether it is produced by a different complement of dilators altogether is unknown. We have also shown that over 2 min of contraction, the magnitude of the vasodilation increased with an increase in stimulus frequency and contraction frequency (41) . Increases in the magnitude of the vasodilations could result from increasing the concentrations of the same complement of vasodilators or could result from a different complement of vasodilators as the stimulation parameters change but whether different stimulation parameters produce a different complement of vasodilators over time is unknown. Murrant and Sarelius (42) have previously shown that a complement of vasodilators and processes (ADO, NO, and K ATP channels) is responsible for arteriolar dilation under one contraction condition (4 Hz twitch contractions) over 2 min. We now need to understand whether the complement of vasodilators remains constant while stimulation parameters are varied or whether the complement of vasodilators changes as stimulation parameters are varied.
To test the hypothesis that changes in both stimulus and contraction frequency create different complements of vasodilators, we measured arteriolar dilation in response to muscle contraction using a range of stimulus frequencies (4, 20, and 40 Hz) and contraction frequencies [6, 15 , and 60 contractions/ min (cpm)] in the absence and the presence of blockers and antagonists for dilators that we have previously shown to be involved in contraction-induced vasodilation. These data are essential in determining the significance of stimulation parameters in generating different complements of vasodilators associated with active hyperemia. If different stimulation parameters prove to generate different vasodilators then these data will provide a new direction in a field that has been in conflict for decades.
METHODS
All experimental procedures were approved by the institutional animal care and use committee and were conducted in accordance with the guidelines of the Canadian Council on Animal Care as set out in the Guide for the Care and Use of Experimental Animals.
Blood Perfused Cremaster muscle In Situ
Adult male Golden hamsters (100 -130 g) were anesthetized with pentobarbital sodium (70 mg/kg ip) and tracheotomized. Polyethelyne catheters (outer tip diameter ϳ0.5 mm) were placed in the left femoral artery and vein to monitor mean arterial pressure and for supplemental pentobarbital administration, respectively. Supplemental pentobarbital was given as needed during surgery and constantly infused throughout the experimental protocol (10 mg/ml saline, 0.56 ml/h). Hamster esophageal temperature was maintained at 37°C via convective heat from a coiled, water-filled glass tube (42.0°C) secured under the hamster.
The right cremaster was prepared for in situ microscopy as previously described (3, 40) . Briefly, the cremaster was isolated, cut longitudinally, separated from the testis and epididymis, and gently spread over a semicircular lucite platform. The edges of the tissue were secured with insect pins to maintain tension but not stretch the muscle. Once exposed, the cremaster muscle was constantly superfused with a bicarbonate-buffered salt solution containing (in mmol/l) 131.9 NaCl, 4.7 KCl, 2.0 CaCl 2, 1.2 MgSO4, 30 NaHCO3, and 0.3 mg/l tubocurarine equilibrated with gas containing 5% CO2-95% N2 (pH 7.35-7.45). Cremaster muscle temperature was maintained at 34.0°C. Following the surgery, all preparations were allowed to equilibrate for 45-60 min before data collection.
The cremaster microvasculature was visualized by transillumination with a tungsten lamp and with an Olympus BX51WI microscope using a ϫ20 long working distance objective (numerical aperture 0.50) and a ϫ1.6 magnification changer. The microscope image was displayed via a video camera (DXC-390; Sony) on a monitor and recorded on a videotape recorder (SVO-9600MD; Sony). Final magnification of the site was ϫ2,000. Diameter measurements were reproducible to within Ϯ 0.3 m.
Transverse arterioles with a maximum diameter of ϳ40 m were observed. These arterioles do not run approximately parallel with a paired vein, and they are the third arteriolar branch order up from the capillaries. Transverse arterioles were identified as previously described (40) . Our only selection criterion required that muscle fibers associated with the transverse arteriole run approximately perpendicular to the vessel. This architecture is common and can be found in all areas of the tissue preparation.
Muscle fiber bundles (3-5 fibers) were stimulated directly using a platinum wire microelectrode (tip diameter ϳ25 m) that was placed in close proximity to, but not touching, muscle fibers running approximately perpendicular to an arteriole (observation site). The microelectrode was positioned at least 1,000 m away from the chosen site of the arteriole/stimulated muscle fiber intersection. Tubocurarine (nicotinic cholinergic membrane receptor antagonist) was added to the superfusate to ensure direct electrode stimulation of the skeletal muscle cells and not nervous stimulation of the muscle fibers. Blocking nicotinic cholinergic membrane receptors on the skeletal muscle ensured that if a motor nerve was stimulated by the electrode then the resulting ACh release would not stimulate skeletal muscle cell contraction. Therefore, the addition of tubocurarine isolated any muscle contraction to the control of the electrode only. The ground electrode was placed in the superfusate around the outer rim of the tissue support pedestal. Each stimulus was a square wave pulse of 0.4 ms duration and 8 -15 volts (Grass S48 stimulator, Quincy, MA). The voltage was adjusted to maximally stimulate four to five muscle fibers and then kept constant throughout the duration of the experiment.
After the equilibration period, arteriolar diameter at the observation site was continuously recorded for 1 min before muscle stimulation, during the 2-min contraction period, and for 2 min following each contraction period. Muscle fibers were stimulated to contract using varying trains of impulses to generate twitch and tetanic contractions. Trains consist of a set number of impulses (or action potentials) delivered within a specific duration. The number of impulses in a train is referred to as the stimulus frequency; the duration of the train of impulses is referred to as the train duration. The number of trains delivered every minute is referred to as the contraction frequency. Muscle fibers were stimulated for a constant train duration of 250 ms in all protocols. Train duration was fixed, since we have found that it is the least influential stimulation parameter in determining the magnitude of dilation (41) . Protocol 1 tested for the affects of stimulus frequency in altering dilator production; therefore, muscle fibers were stimulated with a constant contraction frequency (15 cpm) and randomized stimulus frequencies of 4, 20, and 40 Hz. This range of stimulus frequencies represents the stimulus parameters that produce twitch, submaximal tetanic (submaximal for force generation), and maximal tetanic contractions (41) . Protocol 2 tested for the affects of contraction frequency on dilator production; therefore, muscle fibers were stimulated at a constant stimulus frequency (20 Hz) and randomized contraction frequencies of 6, 15, and 60 cpm. This range of contraction frequencies represents a low, intermediate, and high contraction frequency. Both protocols contain the contraction protocol where stimulus frequency is 20 Hz and contraction frequency is 15 cpm to monitor our internal consistency. A 5-min rest period was allowed between each 2-min contraction set, and arteriolar diameter had fully recovered to precontraction diameter before the next contraction set.
We tested for a role of K ϩ , KATP channel activity, ADO, and NO in the dilations to varying stimulus frequencies by superfusing the cremaster muscles with either an inhibitor of a source of K ϩ by inhibition of voltage-dependent K ϩ channels [Kv; 3 ϫ 10 Ϫ4 M 3,4-diaminopyridine (DAP)], a K ATP channel inhibitor [10 Ϫ5 M glibenclamide (GLIB); see Ref. 42] , an inhibitor of ADO receptors [10 Ϫ6 M xanthine amine cogener (XAC)], or an inhibitor of a source of NO [the NO synthase (NOS) inhibitor nitro-L-arginine methyl ester (L-NAME; 10 Ϫ6 M)] for 30 min and then repeating the contraction sets in protocols 1 or 2. L-NAME application produced a significant basal arteriolar vasoconstriction indicating that NO is a significant component in establishing resting, baseline diameter. Therefore, during the L-NAME application, we also added 10 Ϫ7 S-nitroso-Nacetylpenicillamine (SNAP), an NO donor, to maintain the normal baseline contribution of NO to the diameter of the arteriole at rest. Following the contraction sets in the presence of the blockers, the drugs were washed out for 30 min, and the contraction sets were repeated to monitor recovery of the vasodilatory activity. All chemicals were obtained from Sigma-Aldrich Chemical.
We observed that both XAC and L-NAME plus SNAP were effective at blocking dilations at lower stimulus and contraction frequencies but not higher stimulus or contraction frequencies. It is possible that, with increasing stimulus or contraction frequency, the concentration of ADO and NO produced and released also increased. Because the concentration of our blockers was constant throughout all stimulus and contraction frequencies, it is possible that our block became less effective as the concentration of the dilators became higher. To more accurately interpret our data in this regard, we exposed arterioles to incrementally increasing concentrations of ADO (10 Ϫ9 to 10 Ϫ4 M; n ϭ 4) at 2-min intervals and ACh (10 Ϫ9 to 10 Ϫ4 M; n ϭ 4) at 5-min intervals in the absence and the presence of 10
Ϫ6
M XAC and 10 Ϫ6 M L-NAME plus 10 Ϫ7 M SNAP, respectively, to determine if there were concentrations of agonists for which our blockers were effective.
Following each experiment, arteriolar diameters were recorded after 2 min of superfusion of the preparation with 10 Ϫ4 M sodium nitroprusside (SNP, considered to produce maximal dilation). Animals were subsequently euthanized with an overdose of pentobarbital sodium (70 mg/kg iv) to effect.
Hamster Cremaster Strips In Vitro
In the in situ protocol, skeletal muscle cells were directly exposed to 3 ϫ 10 Ϫ5 M DAP, 10 Ϫ5 M GLIB, 10 Ϫ6 M XAC, and 10 Ϫ5 M L-NAME plus 10 Ϫ7 M SNAP, each of which could alter skeletal muscle function that may, in turn, result in an altered dilatory response to muscle contraction. To determine if there were systematic effects of the blockers on the force of contraction of the cremaster muscle fibers, following the in situ experiments, the left cremaster muscle was exteriorized and cut into two strips. Each strip was tied at the ends with 5.0-gauge suture silk and hung in a tissue chamber containing Krebs-Henseleit solution consisting of, in mmol/l: 118 NaCl, 4.75 KCl, 2.54 CaCl 2, 1.18 KH2PO4, 1.18 MgSO4, 24.8 NaHCO3, and 10 glucose. The solution contained 0.3 mg/l tubocurarine and 10 U insulin/l and was aerated continuously with 95% O 2-5% CO2 at 27°C (pH 7.4).
The cremaster strips were attached to a fixed point at one end and a force transducer [either model FT03 (Grass Medical Instruments) or model 60 -2995 (Harvard Apparatus, Southmatic, MA)] on the other. Stimulating electrodes were fixed at each side of the muscle. The length of each muscle was adjusted for maximal force development. After a 1-h equilibration period, muscle fibers were stimulated as in the in situ protocols: protocol 1: constant train duration of 250 ms, constant contraction frequency (15 cpm), and randomized stimulus frequencies of 4, 20, and 40 Hz, each for 2 min or protocol 2: constant train duration of 250 ms, constant stimulus frequency (20 Hz), and randomized contraction frequencies of 6, 15, and 60 cpm, each for 2 min. Force of contraction was measured as muscles were stimulated over a range of stimulation parameters with a supramaximal voltage (100 V). One of the pair of muscle strips (experimental) was then incubated with either 3 ϫ 10 Ϫ5 M DAP (n ϭ 6), 10 Ϫ5 M GLIB (n ϭ 6), 10 Ϫ6 M XAC (n ϭ 6) or 10 Ϫ5 M L-NAME plus 10 Ϫ7 M SNAP (n ϭ 6) for 30 min; the other of the pair was incubated in Krebs-Henseleit solution to act as an animal and time-matched control. Following the incubation period, the muscles were stimulated again over the above range of stimulation parameters in protocol 1 or protocol 2.
Data were collected and analyzed using the MP100WSW data acquisition system and Acqknowledge III software (Biopac Systems, Goleta, CA) on an IBM computer. Following each experiment, muscle length and wet weight were measured.
Data Analysis and Statistics
All data are reported as means Ϯ SE. Baseline diameter was defined as the diameter just before muscle stimulation. Only one arteriole per preparation was used to collect data, and n indicates the number of arterioles observed. All in situ experiments were videotaped and analyzed off line. Images were digitized, and arteriolar diameters were measured via Image-Pro Plus software. Group means were compared with an ANOVA or a repeated-measures ANOVA where data were analyzed over time. When the ANOVA identified significant differences, a protected least-significant difference was used post hoc to determine if diameter changes were significantly different (50) . Differences were considered significant when P Ͻ 0.05. Linear regression analysis was used to determine the fatigue rates (rate of decline in force over 2 min) for the hamster cremaster strip preparation in vitro.
RESULTS

Blood Perfused Cremaster Muscle In Situ
Mean arterial pressure remained constant between 80 and 100 mmHg over the course of the experiment and did not change during skeletal muscle contraction.
Baseline diameter for the control and experimental conditions as well as maximal diameters are shown in Table 1 . Baseline control and experimental diameters did not differ within either the stimulus or the contraction frequency protocol; therefore, 20 Hz and 15 cpm are shown as representative. Of particular importance is that the baseline data before and during L-NAME plus SNAP application were not significantly different, indicating that we were successful at bringing the baseline diameter back to control levels with the addition of 10 Ϫ7 M SNAP during L-NAME treatment. The maximal diameters did not differ between groups except for maximum diameter of the DAP protocol, which was significantly larger. Significant differences in maximal diameter may alter the dilatory potential (maximal diameter Ϫ baseline diameter) of the blood vessels. To determine whether this was a factor that influenced the magnitude of our observed changes in diameter, we plotted the dilatory potential vs. the change in diameter for each DAP control set under different stimulation parameter conditions and calculated the r 2 value for the relationship for each set (data not shown). We found very low correlations between the change in diameter and dilatory potential (average r 2 value 0.38 Ϯ 0.08), indicating that differences in maximal diameter did not have a significant influence on the ability of the blood vessels to dilate. These data are consistent with data previously published (41) . Figure 1 shows the pattern of inhibition over the tested range of stimulus and contraction frequencies in the presence of DAP. DAP did not have a significant affect on the magnitude of the dilation at any stimulus frequency although there was a Values are means Ϯ SE; n, no. of experiments. Expt, experiment; DAP, 3,4-diaminopyridine; GLIB, glibenclamide; XAC, xanthine amine cogener; L-NAME, N G -nitro-L-arginine methyl ester. Baseline diameters reported here are the vessel diameters just before control contractions and following drug incubation just before experimental contractions. Baseline control and experimental diameters did not differ within the stimulus frequency protocol or within the contraction frequency protocol, therefore 20 Hz and 15 contractions/min (cpm) are shown as representative. *Significant differences between maximal diameters.
trend for an inhibition in the presence of DAP within the first 10 s as stimulus frequency increased (Fig. 1A) . Although there was no significant affect of DAP at 6 cpm (Fig. 1B) The application of GLIB showed a very different pattern of inhibition (Fig. 2) . GLIB inhibited vasodilations produced by all stimulus and contraction frequencies, indicating the involvement of K ATP channels in all stimulation parameters tested. Figure 3 shows that XAC inhibited dilations at stimulus frequencies of 4 and 20 Hz but not 40 Hz (Fig. 3A) while inhibiting dilations at all contraction frequencies (Fig. 3B) . It is interesting to note that, when vasodilation was going to be inhibited, the inhibition started very early in the contraction bout. In some cases, the inhibition of the vasodilation in the presence of XAC resulted in an actual vasoconstriction during contraction. This occurred at low stimulus and contraction frequencies. Figure 4 shows that L-NAME inhibited the dilations at all stimulus frequencies but did not inhibit dilations at all contraction frequencies. L-NAME inhibited the dilations at 6 and 15 cpm but did not attenuate the dilations at 60 cpm.
To aid in the correct interpretation of our data, we tested the effectiveness of 10 Ϫ6 M XAC and 10 Ϫ5 M L-NAME plus 10
Ϫ7
M SNAP at blocking a range of concentrations of ADO and ACh (as a mechanism to produce endothelial-derived NO), respectively. Baseline diameters for the control (18.3 Ϯ 3.1 m) and L-NAME plus SNAP (24.7 Ϯ 2.9 m) experiments were not significantly different from each other, and the maximal diameter of vessels used in this protocol was 46.7 Ϯ 1.8 m. Figure 5A shows that L-NAME plus SNAP were 100% effective at blocking ACh-induced dilations from 10 Ϫ9 to 10 Figure 5B shows that 10 Ϫ6 M XAC was able to block ϳ100% of the change in arteriolar diameter produced by 10 Ϫ9 to 10 Ϫ7 M ADO and 70% of the dilation induced by up to 10
Ϫ4
M ADO. Concentrations of ADO of 10 Ϫ5 M and above produced dilations that were not significantly different from the maximal dilation measured in these vessels.
The vasodilation in response to muscle contraction at all stimulus and contraction frequencies was also recorded after 30 min of washout of any drug applied for most experiments. When the drug caused a significant inhibition of dilation, the recovery dilation following washout of the drug returned to 100% of control vasodilations (111.7 Ϯ 10.9%) with the exception of DAP at 60 cpm where recovery was 44.2 Ϯ 6.7% of control and during L-NAME application, where the average recovery was 79.2 Ϯ 13.3% of control levels. We interpret the lack of complete recovery as an indicator of an insufficient washout duration. When the drug did not cause a significant inhibition of the dilation, the recovery dilation following drug washout was not significantly different from the control dilation (101.1 Ϯ 10.1% of control) with the exception of DAP at 20 Hz (76.8 Ϯ 4.1% of control) and 40 Hz (71.3 Ϯ 9.4% of control) and as well as L-NAME at 60 cpm (65.5 Ϯ 8.8% of control). Our recovery data indicate that the vasodilations to muscle contraction are repeatable over time and that any changes in dilation in the presence of a treatment were due to the effect of the treatment and not due to the lack of reproducibility of the dilations in response to muscle contraction.
Hamster Cremaster Strips In Vitro
We used in vitro experiments using hamster cremaster strips to obtain a force response relative to that produced in situ. We tested the effects of 3 ϫ 10 Ϫ5 M DAP, 10 Ϫ5 M GLIB, 10 Ϫ6 M XAC, or 10 Ϫ5 M L-NAME plus 10 Ϫ7 M SNAP on force generation of cremaster strips in vitro to assess any systematic changes in skeletal muscle force generation in the presence of each of the blockers. We found that exposure to GLIB, XAC, DAP, and L-NAME plus SNAP did not affect the absolute forces generated by the cremaster strips compared with timeand animal-matched controls (Table 2) . Fatigue rates (rate of decline in force) over the 2-min contraction bouts (mimicking the stimulation protocols of the in situ experiments) were not significantly affected following exposure to any of the experimental conditions (Table 3) .
DISCUSSION
These experiments are the first to test for the presence of multiple vasodilators under multiple stimulation conditions, and we found that changing the stimulus frequency and the contraction frequency results in a change in the vasodilator complement involved in arteriolar vasodilation. We show that dilations at low stimulus frequencies were produced by K ATP channels, NO, and ADO; yet, vasodilations in response to high stimulus frequencies were produced by K ATP channels and NO and less influenced by ADO. Dilations to low contraction frequencies were produced by K ATP channels, ADO, and NO while high contraction frequencies were produced by K ATP channels and ADO and K ϩ with less influence of NO. Therefore, the dilations produced by different stimulation parameters were produced by a different complement of vasodilators. These data indicate that stimulation parameters are a significant determinant of type of vasodilator produced.
Experimental Considerations
Significant differences in the maximal diameter of the blood vessels in the DAP groups were observed while observing no significant differences in baseline diameters between groups. Differences in the maximal diameter with no differences in baseline diameter may result in a difference in the dilatory potential of the vessel (dilatory potential ϭ maximal diameter Ϫ baseline diameter). We could not demonstrate strong correlations between the change in diameter and the dilatory potential in this study as well as in previous studies (41) . Thus the difference in maximal diameter does not significantly impact the response of the vessels to muscle contraction or our interpretation of the data.
We did not systematically reach maximum dilation under our stimulation conditions, yet some of the stimulation parameters did induce a maximum diameter change. If maximum diameter is achieved then our bioassay system loses the ability to detect further changes in vasodilation. There was only one condition, the controls for the DAP trial at 60 cpm and 20 Hz, where more than half of the arterioles (7 out of 8) reached maximal diameter. In this case, the presence of DAP inhibited the dilation from control levels; therefore, achieving maximal diameter under control conditions does not impact our interpretation of the data. Correct interpretation of the XAC and L-NAME plus SNAP data required that we test the possibility that our blockers became ineffective in the presence of physiologically relevant concentrations of ADO and NO, respectively. XAC significantly inhibited ADO dilations up to 10 Ϫ4 M ADO. L-NAME significantly inhibited ACh dilation up to 10 Ϫ4 M ACh. Therefore, concentrations of ADO Ͼ10 Ϫ4 M and concentrations of NO greater than that associated with 10 Ϫ4 M ACh would have been needed to render our blockers ineffective. Both 10 Ϫ4 M ADO and 10 Ϫ4 M ACh produce maximal vasodilation yet no stimulation protocol involving XAC or L-NAME plus SNAP caused maximal dilation; therefore, the concentrations of ADO and NO could not have been released at concentrations that would yield our blockers ineffective.
In hamster cremaster strips in vitro, neither absolute forces nor fatigue rates were affected by exposure to any of our experimental drug/blocker conditions. This indicates that, in our in situ preparations, changes in diameter in the presence of the drugs were attributed to the effects of the drug on the vasculature and not the effects of the drugs on skeletal muscle contraction.
Vasodilators Implicated in the Dilatory Response to Muscle Contraction
The vasodilator studies within these experiments were chosen because they were found previously to be involved in vasodilations associated with muscle contraction (2, 42) and they represent a variety of processes associated with muscle contraction, including products of muscle activation (K ϩ and NO), classic products of metabolism (ADO), and K ATP channels that may represent part of the signaling pathway of previously mentioned ADO and NO or may represent the signaling pathway of an important, as-of-yet unidentified, vasodilator. They were also chosen because the timing of their importance may be potentially different, with an expected early role for K ϩ and later role for ADO. Although an exhaustive list of all potential dilators was not studied, it was not necessary to study all dilators to test the hypothesis regarding how they change with different stimulation parameters.
The target of DAP was to inhibit Kv channels on skeletal muscle cells to inhibit a source of the dilator K ϩ during contraction. We show here and have shown previously (2) that blocking Kv channels did not significantly affect either force of contraction or fatigue rate in vitro over the 2-min contraction periods in vitro. Blocking Kv channels on skeletal muscle cells has been shown to amplify force generation (55), but we did not observe significant changes in developed force or fatigue rate under the stimulation conditions used in the current study. Vascular smooth muscle cells and endothelial cells have been shown to have Kv channels. Although the function of Kv channels on endothelial cells (13, 14, 21, 27 ) has yet to be determined, DAP has been shown to cause vasoconstriction of cerebral arterioles by depolarization (34) , possibly through Kv channels on smooth muscle cells (1, 13, 14, 32, 54) . We, however, did not observe a decrease in baseline in the presence of DAP; therefore, blocking Kv on smooth muscle cells or endothelial cells does not appear to alter resting dilator and/or constrictor levels. Kv channels on vascular smooth muscle cells have been shown to be stimulated by cAMP/protein kinase A-dependent mechanisms, which may implicate Kv channel involvement in ADO-induced vasodilations (19, 43, 52) . Therefore, during DAP application, the ADO mechanism may have also been affected. If Kv channels were a significant component of the ADO pathway then the vasodilatory profiles for DAP and XAC over each of the stimulation parameters should look similar, which they did not. Both XAC and DAP application did inhibit vasodilation at high contraction frequencies, but XAC had effects on all stimulus frequencies and contraction frequencies where DAP did not. Therefore, although we cannot rule out that the inhibition by DAP at 60 cpm was due, in part, to a decrease in the effectiveness of ADO, the effects of DAP cannot be explained by inhibition of the ADO pathway alone.
The primary target for our ADO receptor blocker was endothelial cells and smooth muscle cells. Both cell types have been reported to possess A1, A2 A , and A2 B membrane receptor subtypes (37) . ADO receptors have been shown to cause vasodilation through NO-dependent processes and K ATP channels (8, 23, 33) , although the exact location of the K ATP channels (endothelial cells or smooth muscle cells) is unknown. ADO receptors on smooth muscle cells have been shown to facilitate vasodilation through cAMP/protein kinase A-dependent mechanisms, resulting in the opening of K ATP channels, presumably on smooth muscle cells, and the resulting hyperpolarization will cause vasodilation (for review, see Ref. 7) . ADO receptors have been identified on rodent and human skeletal muscle, although the specific membrane receptor subtype complement may differ (37, 44) . Stimulation of skeletal muscle with ADO has shown to increase force generated by fast-twitch muscles and decrease the fatigue rate of both fast- Values are means Ϯ SE. Units are g/min. *Time-and animal-matched controls.
and slow-twitch muscles (44) . In the presence of XAC, we did not observe significant changes in force or fatigue rate in vitro during any of our stimulation protocols; therefore, blocking the effects of ADO had little effect on skeletal muscle performance under our stimulation conditions. In some cases, the inhibition of the vasodilation in the presence of XAC resulted in a vasoconstriction during contraction. This occurred at lower but not higher stimulus and contraction frequencies. The XAC constrictions indicate that, under certain stimulation conditions, ADO was inhibiting the production or expression of a vasoconstrictor that is now able to manifest itself. ADO has been linked to dilate via NO (for review, see Ref. 39) , and NO has been shown to inhibit the sympathetic nervous system locally by decreasing the amount of norepinephrine released (53) . Thus it is possible that, by blocking the ADO pathway, there is an increase in sympathetic nervous system constricting influences. Whether an increase in local sympathetic nervous system influences or other local constricting pathways is responsible for the constriction requires further investigation. L-NAME treatment was used to decrease the release of NO from skeletal muscle during contraction. Skeletal muscle cells have been shown to contain endothelial and neuronal NOS (31, 35) , produce NO at a basal rate at rest, and increase this rate during contraction (4, 24) . NO is partially responsible for the arteriolar diameter at rest, as shown by the addition of L-NAME, causing a vasoconstriction under resting conditions. We successfully restored this basal level of NO by adding SNAP to the superfusion medium. Obviously, the source of NO under such supplementing conditions is different from the physiological source being blocked, but it is essential to try to keep baseline conditions similar to only test the changes in NO levels during contraction. In blocking the production of NO from skeletal muscle, both endothelial cell and/or vascular smooth muscle cell production would also be blocked. The ability of endothelial cells to produce NO is well documented, and there is evidence that vascular smooth muscle cells contain NOS (9, 10, 12) and are capable of producing NO (10) , although the purpose of this autocrine process is not well understood.
Vascular cell NOS is involved in the dilatory pathways for other vasodilators implicated in muscle contraction such as ACh and ADO (8, 23) , and L-NAME application may, therefore, also be blunting the dilatory response imposed by these dilators during contraction. Although we did not test the contribution of ACh in this study, we did test the contribution of ADO. If blocking NO synthesis were to have been primarily due to the inhibition of the ADO signaling pathway then the patterns of inhibition by L-NAME and XAC at each of the contraction and stimulus frequencies should look similar but they do not. Therefore, the effects of L-NAME cannot be accounted for by the inhibition of ADO pathways and its vascular cell contribution alone.
Within our experimental protocols, GLIB application was intended to target K ATP channels on vascular smooth muscle cells or endothelial cells. Although stimulation of K ATP channels on vascular smooth muscle cells produces vasodilation, there is less evidence for K ATP channels on endothelial cells (for reviews, see Refs. 7 and 30). Both ADO and NO (directly, from endothelial cell sources or from ADO-stimulated pathways) have been shown to cause vasodilation through K ATP channels (for review, see Ref . 7); thus, the inhibition of dilation by GLIB may represent the blocking of the signal transduction pathway for multiple vasodilatory products. If ADO stimulated K ATP channels in response to muscle activity then the XAC and GLIB data should be similar, which they are not. Similarly, if NO was stimulating K ATP channels in response to muscle contraction, the L-NAME plus SNAP and GLIB data should be similar yet they are not. Therefore, there are either multiple dilators converging on the function of the K ATP channels, or K ATP channel stimulation represents an independent pathway turned on by an as of yet, unidentified dilator.
It is possible that only two vasodilators produced by skeletal muscle during contraction were tested in this study, K ϩ and ADO. Both NO and K ATP channels could be part of the ADO pathway and the pathways of other vasodilators not tested here. ACh, for example, would vasodilate through NO-dependent pathways (20) . Yet, for the dilators tested in this study, the patterns of vasodilation over varying stimulus and contraction frequencies were very different from each other, indicating that neither NO or K ATP channels accounted entirely for the effects of ADO and K ATP channels and could not account for the effects of NO. These data indicate the prevalence of multiple dilatory pathways with intracellular signaling pathways that overlap and integrate. This idea combined with the idea that the dilatory pathways used are changing depending on the stimulation parameters increases the level of complexity in trying to determine how the system is controlled such that blood flow and metabolism are matched.
How Stimulation Parameters May Affect the Vasodilator Complement
Contraction frequency. Contraction frequency has been shown to have a significant impact on metabolic rate and ATP consumption (22, 51) , a response, at least, of added myosin ATPase activity and added ion pump activity with the increased number of contractions. Contraction frequency has also been shown to acutely upregulate intracellular signaling pathways such mitogen-activated protein kinases (46) and AMP kinase pathways (29) . These data indicate that contraction frequency has the potential to alter intracellular metabolism and signaling, either of which may alter the vasodilatory products released. In the current study, ADO was the classic metabolic vasodilator tested. We would therefore expect that if contraction frequency increased metabolism then ADO would become a more important vasodilator as contraction frequency increased. We observed a similar magnitude of inhibition at all contraction frequencies tested. Recent data regarding the potential extracellular production of ADO during contraction via extracellular 5Ј-nucleotidases (38) and extracellular phosphodiesterases (15) indicate that intracellular metabolic production of ADO may not be the primary source of extracellular ADO during contraction. Our lack of correlation between contraction frequency and ADO involvement would support this hypothesis.
Stimulus frequency. We observed that stimulus frequency was an important determinant of the dilator production during 2 min of skeletal muscle contraction. Stimulus frequency has been shown to not have a large impact on metabolic rate and ATP utilization (51) , especially when force is controlled for (47) . Stimulus frequency does have a significant impact on intracellular calcium concentration (16) (45) . Among the vasodilators tested in this study, skeletal muscle-generated NO is likely Ca 2ϩ dependent, and we observed that L-NAME completely inhibited the dilations induced by all stimulus frequencies. Because the dilation at 40 Hz was larger than those at 20 and 4 Hz, this could be interpreted as a larger inhibition by L-NAME at higher stimulus frequencies, but this relationship would have to be studied further to warrant such a conclusion.
Isolated muscle preparations have shown that K ϩ is released with each action potential (for review, see Ref. 49 ), but the release may not be linearly related to stimulus frequency over multiple stimuli (25, 26) . We show that K ϩ involvement does not increase as stimulus frequency increases over 2 min. We have shown previously that K ϩ is involved in the dilation in response to a single contraction over a range of stimulus frequencies (2) in the absence of a contraction frequency, and our data here indicate that there may be a role for K ϩ within the first 10 s of contraction, but its role is minimized over time and its role changes depending on contraction frequency. The role for K ϩ involvement is a complex one; K ϩ dilations have been shown to be transient, and whether K ϩ acts as a dilator or constrictor is dependent on its concentration; 15 mM will produce dilation while 40 mM will cause constriction (11, 48, 57) . The concentrations of K ϩ measured from contracting muscle range from 4 to 5 mM for a single action potential (25) to 52.4 mM (17) depending on skeletal muscle type and stimulation parameters. Therefore, the role of K ϩ in producing vasodilation over time will potentially be complex.
Our model and experimental protocol are designed to mimic what part of a motor unit may be doing during skeletal muscle stimulation. With this model, we can individually control the independent stimulation parameters that the nervous system uses to change skeletal muscle function. These independent variables (stimulus frequency, train duration, contraction frequency, and time over which the muscle fibers are active) are used to change dependent variables such as muscle force. Although not measured in situ, our in vitro data indicate that force increased as stimulus frequency increased in our protocol. Force generated by a muscle is dependent on stimulus frequency, the number of fibers being stimulated, train duration (if very short train durations are being considered), muscle length, and the load on the muscle. Force has been shown to be an important variable in the magnitude of arteriolar vasodilation (56) . Our data would support that force and the magnitude of vasodilation are related as forces generated in the present study increase with increases in stimulus frequency. Indeed, our conclusions regarding the importance of stimulus frequency in determining the dilators produced can be extended to force, since both are changing in our protocol at the same time. However, force may not necessarily be the primary determinant of the type of vasodilator produced under all circumstances. At the whole muscle level, a muscle fiber (within a motor unit) can be stimulated to contract, which would result in vasodilator production. To increase force, another muscle fiber (within another motor unit) could be stimulated to contract. If the stimulation conditions of both muscle fibers were the same, then the expectation is that the dilators released by each muscle fiber would be the same and there would now just be more of the same dilators released. Under these conditions, we would not expect the types of dilators to change, but force would have increased. Given this potential to increase force and not change the type of dilator produced, we have chosen to investigate the determinants of force as the primary determinants of dilator production. We show that, with all other determinants of force held constant, stimulus frequency does affect the type of dilator produced, and, since force is a variable determined by stimulus frequency, we conclude that stimulus frequency is a primary determinant of the type of dilator produced. We are testing one of the many variables on which force is dependent; to make conclusions regarding force requires that we know about the effects of these more fundamental variables first. Further studies would be required to specifically determine the role of force in changing the nature of the vasodilator, but these experiments will invariably have to change the above-listed independent variables to make this determination.
In summary, we have shown that the vasodilator complement after 2 min of skeletal muscle contraction is dependent on the stimulation parameters used to contract the skeletal muscle cells. We have demonstrated that multiple dilators are responsible for the arteriolar dilations in response to skeletal muscle contraction over 2 min, and their relative importance was determined by both the stimulus frequency and contraction frequency. These data support the hypothesis that stimulation parameters are an important determinant of the dilator complement. Given the importance of skeletal muscle stimulation parameters in determining the vasodilators produced, it is critical that attention be paid to these variables and to how skeletal muscle cells are activated when trying to determine the vasodilators involved in producing active hyperemia.
